Navigation Links
First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals' Lead Therapeutic Candidate for Treatment of Migraine, ALD403
Date:3/20/2013

BOTHELL, Wash., March 20, 2013 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced the dosing of the first patients in a proof-of-concept Phase 2 clinical study of its antibody therapeutic candidate, ALD403, targeting calcitonin gene-related peptide (CGRP) for treatment of migraine.

The double-blind, placebo-controlled, randomized study will evaluate the safety and efficacy of ALD403 administered monthly. One hundred and sixty patients with frequent, episodic migraines will be enrolled in the study across six sites for six months. Patients in the study will have experienced between four and 14 migraines per month in at least three months prior to enrollment and take acute migraine medication.

"Despite the enormous progress made in acute treatments for migraine, substantial unmet needs remain for patients experiencing multiple migraines per month," said Richard Lipton , M.D., principal investigator, professor of neurology and epidemiology at Albert Einstein College of Medicine in Bronx, New York, and director of the Montefiore Headache Center. "Most currently available preventive treatments for migraine are taken on a daily basis, reduce migraine frequency by 50 percent in about half of users and often produce significant side effects.  A biologic targeting CGRP and offering higher rates of efficacy, along with less frequent dosing and fewer side effects, could have a tremendous benefit for patients." 

Added Randall Schatzman , Ph.D., president and chief executive officer of Alder Biopharmaceuticals, "Alder is changing the paradigm for the treatment of migraine from abortive care at the time of migraine onset to a preventative approach, and our team has developed a highly specific therapeutic candidate with the potential to prevent the disorder before it begins that we believe has the ability
'/>"/>

SOURCE Alder Biopharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
2. Wyckoff Heights Medical Center Is First New York Hospital to Offer Asthmapolis Mobile Asthma Management Program
3. Quest Diagnostics Launches Dementia Diagnostic Panel, First in Industry for Treatable Forms of Cognitive Impairment Based on Medical Guidelines
4. ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
5. Maddak Inc. Opens Possibilities For Disability Community With Launch Of Morph Wheels, First-Ever Foldable Wheelchair Wheels
6. N30 Pharmaceuticals Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
7. ISASS13 Shows Growth in New Exhibitors and First-Time Attendees
8. First Product in Tris Pharmas Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris
9. PDL BioPharma Provides First Quarter 2013 Royalty Revenue Guidance of $92 Million
10. UPDATE: Zimmer Announces 11% Increase in Quarterly Dividend for First Quarter of 2013
11. Zimmer Announces 11% Increase in Quarterly Dividend for First Quarter of 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 Semler Scientific, ... assessment company that develops, manufactures and markets products that ... diseases, today reported financial results for the first quarter ... first quarter of 2015, Semler reported continued progress with ... over quarter revenue growth of 14%," said Doug ...
(Date:5/1/2015)... , May 1, 2015  Shares of Aerie Pharmaceuticals, ... their value yesterday following the results of the Phase ... Rhopressa.  Despite the trial failing to meet its end ... results may come from future studies. An ... overview, current pipeline, financial review, analyst summary, valuation, and ...
(Date:4/30/2015)... , April 30, 2015  Accuray Incorporated (Nasdaq: ... signed an agreement with MIM Software Inc. to ... ® and CyberKnife ® product portfolios. The ... MIM technology. This is Accuray,s second collaboration with ... of the first iPad-based treatment plan review capability, ...
Breaking Medicine Technology:Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3
... who take non-steroidal anti-inflammatory drugs three times a day for ... have erectile dysfunction compared to men who do not take ... online in The Journal of Urology . ... finding, this observational study used electronic health records, an automated ...
... Md., March 2, 2011 Do you use a prescription ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Federal regulators aim to take certain ... symptoms off the U.S. market. These products ... evaluated by FDA to assure that they are safe, effective, ...
Cached Medicine Technology:Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 2Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 3
(Date:5/2/2015)... May 03, 2015 As one of ... the prestigious Safety and Health Achievement and Recognition Program ... to be chosen by the Illinois Department of Labor ... achieved and maintained SHARP certification by the Occupational Safety ... as Essentra has continued to meet or exceed all ...
(Date:5/2/2015)... 2015 It’s a pattern that won’t ... strikes anywhere on this planet, cyber scammers will immediately ... compassion for their own personal gain. And on ... Team) issued an alert titled “Nepal Earthquake Disaster ... citing the earthquake in Nepal. The scam emails may ...
(Date:5/2/2015)... 2015 As a nonsurgical staple ... the face, neck and décolleté, radiofrequency energy is ... potential for the success of vulvovaginal rejuvenation. In ... Advisory Council, ThermiGyn’s Women’s Health Clinical Advisory Board ... that ThermiGyn’s temperature controlled radio frequency, specifically that ...
(Date:5/1/2015)... Pioneer Millworks, the largest reclaimed wood ... their reclaimed wood products at the 27th annual International ... in NYC this May. Their newest offerings, Vat 35, ... texture and color to North America's platform for global ... and color in the design world and we're excited ...
(Date:5/1/2015)... 2015 It’s raining bills on Capitol Hill ... to expand federal support for telemedicine. , “Such ... been working with Congress,” said Jonathan Linkous, CEO of the ... nation is poised to embrace the use of telecommunications in ... in fulfilling ATA’s mission to improve quality, access, equity and ...
Breaking Medicine News(10 mins):Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2
... Water Quality and Health Council Calls for Greater Surface Disinfection to ... you cough without covering your mouth while standing in the lunch ... the morning bus? Nearly all Americans (96 percent) have seen ... (77 percent) say they are guilty themselves. , Even with ...
... ... the launch of MethoCult® Express, an innovative methylcellulose-based medium specifically formulated to allow ... , ... British Columbia (PRWEB) October 8, 2009 -- STEMCELL Technologies Inc. , a ...
... ... a leading direct-to-consumer provider of premium dietary supplements, announces the release of their ... ... Products ®, a leading direct-to-consumer provider of premium dietary supplements, announces the release ...
... acute liver failure caused by acetaminophen poisoning also can treat ... before severe injury occurs, UT Southwestern Medical Center researchers and ... liver failure occurs when cells in the liver die quickly, ... Patients often end up in a hepatic coma as a ...
... SAN BERNARDINO, Calif., Oct. 7 Last Sunday, the Inland ... Historic Redlands to fight cancer. With more than 6,000 ... Inland Women Fighting Cancer,s 2nd Annual Believe and Walk ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20091007/LA89260LOGO ) , The sea of ...
... Center,s Health Care Report Urge Joint Leadership on Health Reform ... statement released by Bipartisan Policy Center Founders and Advisory Board ... , "After 14 months of work, on June 17, 2009, ... the culmination of months of work as advisors to the ...
Cached Medicine News:Health News:Gross Germ-Spreading Behaviors Remain the Norm, Despite Flu Season Concerns 2Health News:Gross Germ-Spreading Behaviors Remain the Norm, Despite Flu Season Concerns 3Health News:STEMCELL Technologies Inc. Introduces MethoCult Express for Cord Blood Banks and Transplant Centers 2Health News:Purity Products Releases Their Brand New Mediterranean Diet Resveratrol Formula 2Health News:Medication effective for acute liver failure in early stages of disease 2Health News:Stater Bros. Charities Collects $328,000 for the Cure in 'I Believe Walk'... Over 6,000 Participate 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: